NCT01550744View on ClinicalTrials.gov

"A Study of Ustekinumab to Evaluate a Subject-tailored Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis"

PHASE3CompletedINTERVENTIONAL
Enrollment

478

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

May 31, 2015

Study Completion Date

July 31, 2015

Conditions
Psoriasis
Interventions
DRUG

Ustekinumab 45 mg

Form = Injection, route = subcutaneous

DRUG

Ustekinumab 90 mg

Form = Injection, route = subcutaneous

DRUG

Placebo

Form = Injection, route = subcutaneous

Trial Locations (40)

Unknown

Birmingham

Bakersfield

Irvine

Los Angeles

San Diego

San Francisco

Santa Monica

Denver

Bridgeport

Coral Gables

Saint Augustine

Tampa

Chicago

Indianapolis

Plainfield

Louisville

New Orleans

Boston

Troy

Fridley

St Louis

Henderson

Lebanon

East Windsor

New York

The Bronx

Williamsville

Gahanna

Norman

Portland

Pittsburgh

Yardley

Johnston

Nashville

Arlington

Dallas

Salt Lake City

Norfolk

Spokane

Clarksburg

Sponsors
All Listed Sponsors
lead

Janssen Biotech, Inc.

INDUSTRY

NCT01550744 - "A Study of Ustekinumab to Evaluate a Subject-tailored Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis" | Biotech Hunter | Biotech Hunter